NCT02575456View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Ebola Disease
Interventions
BIOLOGICAL

Ebola Vaccine

BIOLOGICAL

Placebo

control

Trial Locations (1)

Unknown

Dr. Alie H Wurie, Freetown

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biotechnology

OTHER

collaborator

Tianjin Cansino Biotechnology Inc

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK